Riskpilot← Back to searchSign inGet full accessNext2Vet AB
ABActiveOrg 5568875057Östra Zinkgatan 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201217 employees
Revenue 2024
SEK 87,4M
+2% vs 2023
EBITDA margin
0.6%
-90% vs 2023
Equity ratio
39.6%
Financial strength
Net profit 2024
SEK 1K
-100% vs 2023
| Revenue | SEK 87,4M | +2% |
| EBITDA | SEK 481K | -90% |
| Net profit | SEK 1K | -100% |
| Total assets | SEK 47,8M | +8% |
| Equity | SEK 18,9M | +0% |
| Employees | 17 | — |
Legal name
Next2Vet AB
Org number
5568875057
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 mars 2012
Share capital
SEK 50 000
Employees
17 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva grossisthandel med veterinära förbrukningsvaror och medicinteknisk utrustning.
Address
Östra Zinkgatan 2
Phone
+46702120113
Email
johan@next2vet.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 42 195 | 44 212 | 51 220 | 61 030 | 77 707 | 77 194 | 85 290 | 87 363 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 1 806 | 2 102 | 2 540 | 2 073 | 2 521 | 7 316 | 5 914 | 10 513 | 4 711 | 481 |
| Depreciation & amort. | −140 | −145 | −36 | −30 | −30 | −42 | −67 | −90 | −137 | −185 |
| EBIT | 1 666 | 1 957 | 2 504 | 2 043 | 2 491 | 7 274 | 5 847 | 10 423 | 4 574 | 296 |
| Net financials | −164 | −176 | −199 | −252 | −256 | −301 | −226 | −442 | −443 | −430 |
| Profit before tax | 1 492 | 1 312 | 2 286 | 1 801 | 2 245 | 6 981 | 4 220 | 7 700 | 4 131 | 57 |
| Tax | −31 | −297 | −517 | −416 | −499 | −1 503 | −881 | −1 608 | −908 | −56 |
| Net profit | 1 461 | 1 015 | 1 769 | 1 385 | 1 746 | 5 478 | 3 339 | 6 092 | 3 223 | 1 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 10 443 | 12 417 | 16 093 | 18 183 | 18 500 | 23 659 | 32 035 | 41 544 | 44 449 | 47 810 |
| Equity | 1 525 | 2 540 | 2 894 | 3 395 | 4 448 | 9 056 | 9 595 | 15 687 | 18 910 | 18 910 |
| Long-term debt | 2 832 | 2 225 | 4 753 | 4 527 | 3 515 | 3 515 | 748 | 10 000 | 10 000 | 10 000 |
| Short-term debt | 6 039 | 7 136 | 7 909 | 9 736 | 10 019 | 10 578 | 19 781 | 11 665 | 11 347 | 14 898 |
| Total debt | 8 871 | 9 361 | 12 662 | 14 263 | 13 534 | 14 093 | 20 529 | 21 665 | 21 347 | 24 898 |
EBITDA margin
0.6%
This company
15.8%
Market median
-96% vs market
20152024
Equity ratio
39.6%
This company
38.2%
Market median
+4% vs market
20152024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20152024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20152024
Asset turnover
1.83×
This company
1.12×
Market median
+63% vs market
20152024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CJ Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
PS | Audit | 2022 | — | — |
HR Audit | Audit | 2021 | — | — |
JE Chief Auditor | Chief Auditor | 2025 | — | — |
SJ Chief Auditor | Chief Auditor | 2022 | — | — |
LH Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Kruuse Svenska Aktiebolag | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JÖRGEN KRUUSE A/S
Next2Vet AB Board members of Next2Vet AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Johan Rydén | Chief Executive Officer | 0 companies |
| Petter Sebastian Rankell | Audit | 0 companies |
| Hans Ragnar Olsson | Audit | 0 companies |
| Josefine Elisabeth Johansson | Chief Auditor | 0 companies |
| Sven Jakob Tenselius | Chief Auditor | 0 companies |
| Lars Håkan Olsson | Chief Executive Officer | 0 companies |
| Lars Hautorn Vilhelmsen | Chairman | 0 companies |
| Mads Alkærsig | Board of Directors | 0 companies |
| Jan Olof Swedin | Board of Directors | 0 companies |
| Sten Evert Wahlström | Chairman | 0 companies |
| Danny Ankjær | Board of Directors | 0 companies |